{
    "clinical_study": {
        "@rank": "23357", 
        "acronym": "Cranio-2", 
        "arm_group": [
            {
                "arm_group_label": "Skull bone reconstruction", 
                "arm_group_type": "Experimental", 
                "description": "Patients with skull bone defect"
            }, 
            {
                "arm_group_label": "Orbital floor defect", 
                "arm_group_type": "Experimental", 
                "description": "Patients with orbital floor defect"
            }
        ], 
        "brief_summary": {
            "textblock": "Bioactive fibre-reinforced composite implant is used for reconstruction of skull bone\n      defects and orbital floor defects.\n\n      Functional and aesthetic outcome is assessed by patient and doctor."
        }, 
        "brief_title": "Clinical Study of FRC Implant to Treat Skull Bone Defects", 
        "completion_date": {
            "#text": "December 2019", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Skull Bone Defect", 
            "Craniofacial Bone", 
            "Reconstruction", 
            "Fibre-reinforced Composite"
        ], 
        "detailed_description": {
            "textblock": "Development phase: Clinical trial Objectives: Assessment of functional and aesthetic outcome\n      Methodology: Intervention study Sample size: 35+20+25 Main criteria for inclusion: Skull\n      bone defect OR orbital floor fracture\n\n      Investigational drug/treatment, dose and mode of administration: FRC implant Comparative\n      drug(s)/placebo/treatment, dose and mode of administration:  -\n\n      Duration of treatment:  2 years of follow-up\n\n      Assessments:\n\n      Clinical outcome and radiologic assesment Functional and aesthetic outcome with Visual\n      Analog Scale (VAS). Pain assessment with VAS.\n\n      Statistical methods:\n\n      Adequate statistical methods for publishing in international peer-reviewed journals."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Study arm 1:\n\n          -  patients with skull bone defect\n\n          -  reconstruction indications fullfilled\n\n        Study arm 2:\n\n          -  patients with orbital floor defect\n\n          -  reconstruction indication fullfilled\n\n        Exclusion Criteria:\n\n          -  if informed consent cannot be obtained"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01874613", 
            "org_study_id": "T97/2011"
        }, 
        "intervention": [
            {
                "arm_group_label": "Skull bone reconstruction", 
                "intervention_name": "Reconstruction of skull bone defect with bioactive FRC implant", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Orbital floor defect", 
                "intervention_name": "Reconstruction of orbital floor defect with bioactive FRC implant", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Craniofacial bone reconstruction", 
            "fibre-reinforced composite", 
            "bioactive glass", 
            "craniotomy", 
            "skull bone defect"
        ], 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "contact": {
                "email": "kalle.aitasalo@tyks.fi", 
                "last_name": "Kalle J Aitasalo, PhD", 
                "phone": "35823130000"
            }, 
            "facility": {
                "address": {
                    "city": "Turku", 
                    "country": "Finland", 
                    "state": "N/A = Not Applicable", 
                    "zip": "20521"
                }, 
                "name": "Department of Otorhinolaryngology"
            }, 
            "investigator": [
                {
                    "last_name": "Jaakko Piitulainen, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Jami Rekola, PhD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Finland"
        }, 
        "number_of_arms": "2", 
        "official_title": "Clinical Study of Skull Defect Reconstruction With Patient-specific Fibre-reinforced Composite Implant", 
        "overall_contact": {
            "email": "kalle.aitasalo@tyks.fi", 
            "last_name": "Kalle J Aitasalo, Professor", 
            "phone": "+358 2 313000"
        }, 
        "overall_official": {
            "affiliation": "Turku University Hospital", 
            "last_name": "Kalle J Aitasalo, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Finland: National Supervisory Authority for Welfare and Health", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "After reconstruction, patient follow-up protocol follows to assess functional outcome, including safety.\nFollow-up is done at timepoints of 1 week, 1 month, 3 months, 6 months and after that every 6 month up to 2 years post-operatively. After this the follow-up is continued yearly, if necessary.\nVisual and manual assessment is done by a doctor. Lateral and PA skull rtg is obtained to assess the fixation and position of the implant.\nC-reactive protein level and leukocyte level is measured to assess the possible inflammation.", 
            "measure": "Functional outcome", 
            "safety_issue": "Yes", 
            "time_frame": "2 year follow-up"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01874613"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "After reconstruction, patient follow-up protocol follows to assess aesthetic outcome.\nFollow-up is done at timepoints of 1 week, 1 month, 3 months, 6 months and after that every 6 month up to 2 years post-operatively. After this the follow-up is continued yearly, if necessary.\nVisual and manual assessment is done by a doctor. Visual Analog Scale (VAS) is used by patient to assess\nfunctional outcome\naesthetic outcome\npain Lateral and PA skull rtg is obtained to assess the fixation and position of the implant.\nC-reactive protein level and leukocyte level is measured to assess the possible inflammation.", 
            "measure": "Aesthetic outcome", 
            "safety_issue": "No", 
            "time_frame": "2 years post-operatively"
        }, 
        "source": "Turku University Hospital", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Oulu University Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Turku Clinical Biomaterials Centre", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Turku University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}